Biocon Limited has informed the Exchange regarding a press release dated April 10, 2025, titled "Biocon Biologics Announces U.S. FDA Approval for Jobevne , Biosimilar Bevacizumab, Expanding Its Oncology Portfolio".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Biologics, the biosimilars arm of Biocon Limited, has received U.S. FDA approval for Jobevne, a biosimilar of Bevacizumab used in oncology treatment. This approval adds to the company's oncology biosimilar portfolio and allows it to compete in the U.S. market for this cancer therapy. Bevacizumab is widely used for treating various cancers including colorectal, lung, and ovarian cancers. The approval expands Biocon Biologics' presence in the high-value U.S. oncology market. This is part of Biocon Biologics' broader strategy to grow its share of the global biosimilars market.
Positive for shareholders — U.S. FDA approval opens a significant revenue opportunity in a large oncology market, potentially boosting Biocon Biologics' earnings and supporting the parent company's growth outlook.